Drug Combination Details
General Information of the Combination (ID: C69733) | |||||
---|---|---|---|---|---|
Name | Silibinin NP Info | + | IPI-549 Drug Info | ||
Structure | + | ||||
Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Biological
Regulation |
Down-regulation | Regulatory T cells and myeloid suppressor cells | ||||
In-vivo Model | 4T1 cells was inoculated subcutaneously into the right mammary glands of female balb/c mice. | |||||
Experimental
Result(s) |
Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment. |
References | ||||
---|---|---|---|---|
Reference 1 | Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment. Int J Pharm. 2020 May 15;581:119239. |